Effect of oral Lactococcus lactis containing endostatin on 1, 2-dimethylhydrazine-induced colon tumor in rats

Table 1 Average final body weight, relative liver and kidney weights, and food consumption data (mean±SD)

Group	Treatment		Final body	Relative liver	Relative kidney	Food consumption
		n	Weight, g	Weight, g	Weight, g	(g/rat/d)
1	DMH+endostatin	10	379.0±24.9a	2.94±0.26	0.56±0.12	18.02
2	DMH+L lactis	10	395.0±36.5a	3.05±0.25	0.56±0.08	18.00
3	DMH	10	383.5±19.2a	3.10±0.40	0.55±0.07	18.48
4	Saline+vehicle	10	439.5±39.3	3.09±0.35	0.56±0.12	20.07

^aP<0.05 vs group 4.

Table 2 Colon tumor incidence, classification, multiplicity, tumor volume, and stage in rats treated with DMH with or without endostatin (mean±SD)

Treatment		Incidence	Adenoma	Carcinoma	Multiplicity	Tumor volume	Duke's stage
	n	n (%)	n (%)	n (%)	number	mm3	A	B	C
DMH+endostatin	10	10(100)	5 (50)	5 (50)	2.50±1.80	2.35±1.84	1	4	-a
DMH+L lactis	10	9(90)	2 (22)	7 (78)	2.67±1.47	2.54±2.00	4	6	-a
DMH	10	10 (100)	5 (50)	5 (50)	4.00±2.96	4.31±4.56	2	-	3

^aP<0.05 vs DMH-treated rats.

Table 3 Tumor classification, distribution, and differentiation in rats treated with DMH with or without endostatin

Treatment	Tumor	Classification (%)		Distribution in colon (%)			Differentiated carcinoma (%)
	number	Adenoma	Carcinoma	Proximal	Middle	Distal	Well	Moderately	Poorly
DMH+endostatin	25	16 (64)	9 (36)	12 (48)	9 (36)	4 (16)	6 (66.7)	3 (33.3)a	0
DMH+ L lactis	24	15 (62.5)	9 (37.5)	10 (41.7)	12 (50)	2 (8.3)	6 (66.7)	3 (33.3)a	0
DMH	40	27 (67.5)	13 (32.5)	15 (37.5)	19 (47.5)	6 (15)	3 (23.1)	10 (76.9)	0

^aP<0.05 vs DMH-treated rats.